Abich Financial Wealth Management LLC Takes $460,000 Position in Bristol Myers Squibb Company $BMY

Abich Financial Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 10,199 shares of the biopharmaceutical company’s stock, valued at approximately $460,000.

Several other hedge funds also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC bought a new position in shares of Bristol Myers Squibb during the second quarter valued at approximately $25,000. Harbor Capital Advisors Inc. boosted its holdings in Bristol Myers Squibb by 107.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 313 shares during the period. Total Investment Management Inc. purchased a new position in Bristol Myers Squibb during the 2nd quarter valued at $38,000. Twin Peaks Wealth Advisors LLC bought a new position in Bristol Myers Squibb in the 2nd quarter valued at $40,000. Finally, Mark Sheptoff Financial Planning LLC increased its stake in Bristol Myers Squibb by 233.3% in the second quarter. Mark Sheptoff Financial Planning LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 700 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

BMY has been the topic of a number of research analyst reports. UBS Group upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and upped their price target for the stock from $46.00 to $65.00 in a report on Wednesday, January 7th. Morgan Stanley restated an “underweight” rating and issued a $40.00 target price on shares of Bristol Myers Squibb in a research note on Friday, February 6th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $57.00 price target (up previously from $51.00) on shares of Bristol Myers Squibb in a research note on Tuesday, December 2nd. Leerink Partners boosted their price target on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, November 24th. Eight analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $59.20.

Bristol Myers Squibb Stock Down 0.3%

Shares of Bristol Myers Squibb stock opened at $59.78 on Friday. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. The company has a market cap of $121.69 billion, a P/E ratio of 17.33, a PEG ratio of 0.17 and a beta of 0.29. The firm’s 50 day moving average price is $55.16 and its 200-day moving average price is $49.35. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). The firm had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 70.30%. Bristol Myers Squibb’s revenue was up 1.3% on a year-over-year basis. During the same quarter last year, the business earned $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were paid a dividend of $0.63 per share. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date was Friday, January 2nd. This represents a $2.52 annualized dividend and a yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.